TY - JOUR
T1 - Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
AU - Arai, Hiroyuki
AU - Elliott, Andrew
AU - Millstein, Joshua
AU - Xiu, Joanne
AU - Ou, Fang Shu
AU - Innocenti, Federico
AU - Wang, Jingyuan
AU - Battaglin, Francesca
AU - Jayachandran, Priya
AU - Kawanishi, Natsuko
AU - Soni, Shivani
AU - Zhang, Wu
AU - Sohal, Davendra
AU - Goldberg, Richard M.
AU - Hall, Michael J.
AU - Scott, Aaron J.
AU - Khushman, Mohd
AU - Hwang, Jimmy J.
AU - Lou, Emil
AU - Weinberg, Benjamin A.
AU - Lockhart, Albert Craig
AU - Shields, Anthony Frank
AU - Abraham, Jim P.
AU - Magee, Daniel
AU - Stafford, Phillip
AU - Zhang, Jian
AU - Venook, Alan P.
AU - Korn, W. Michael
AU - Lenz, Heinz Josef
N1 - Funding Information:
DS reports consulting role for Ability Pharmaceuticals, honoraria from Foundation Medicine, Speakers bureau from Incyte, and research funding at institution from Amgen, Apexigen, Bristol-Myers Squibb, Celgene, FibroGen, Genentech, Medimmune, Merck, OncoMed, and Rafael. RMG reports consulting/advisory role for Merck, Taiho Pharmaceutical, Merck KGaA and Novartis, research funding from Bristol-Myers Squibb, and travel paid from Merck KGaA and Merck. WMK reports consulting role for Merck. HJL reports a role of advisory board for Merck KG, Merck, Bayer, Roche/Genentech, G1 Therapeutics, Oncocyte, Fulgent, Jazz Therapeutics, and Bicara. AE, JX, JPA, DM, PS, JZ, and WMK are Caris employee. All remaining authors declare no competing interests.
Funding Information:
We thank all patients who contributed to this study. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233163, P30CA 014089 [to H-JL], Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, and Daniel Butler Research Fund. Also supported in part by funds from Bristol-Myers Squibb, Genentech, and Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/1/5
Y1 - 2022/1/5
N2 - Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In addition, NF1 expression levels were tested for associations with clinical outcomes using data from 431 patients in the CALGB/SWOG 80405 trial. In the Caris dataset, 2.2% of patients had pathogenic or presumed pathogenic NF1 mutations. NF1-mutant tumors more frequently harbored PIK3CA (25.0% vs. 16.7%) and PTEN mutations (24.0% vs. 4.2%) than wild type tumors. Gene set enrichment analysis revealed that MAPK and PI3K pathway signatures were enriched in NF1-mutant tumors. In the CALGB/SWOG 80405 cohort, low NF1 expression was associated with poor prognosis, and high NF1 expression was associated with better efficacy of cetuximab than bevacizumab. Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.
AB - Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In addition, NF1 expression levels were tested for associations with clinical outcomes using data from 431 patients in the CALGB/SWOG 80405 trial. In the Caris dataset, 2.2% of patients had pathogenic or presumed pathogenic NF1 mutations. NF1-mutant tumors more frequently harbored PIK3CA (25.0% vs. 16.7%) and PTEN mutations (24.0% vs. 4.2%) than wild type tumors. Gene set enrichment analysis revealed that MAPK and PI3K pathway signatures were enriched in NF1-mutant tumors. In the CALGB/SWOG 80405 cohort, low NF1 expression was associated with poor prognosis, and high NF1 expression was associated with better efficacy of cetuximab than bevacizumab. Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=85118454846&partnerID=8YFLogxK
U2 - 10.1038/s41388-021-02074-z
DO - 10.1038/s41388-021-02074-z
M3 - Article
C2 - 34728807
AN - SCOPUS:85118454846
SN - 0950-9232
VL - 41
SP - 260
EP - 267
JO - Oncogene
JF - Oncogene
IS - 2
ER -